Pasithea Therapeutics to Present Results of Tolerizing Vaccine Program at Prestigious International Immunotherapy Conference
August 18, 2022 08:00 ET
|
Pasithea
-- Annual “From Laboratory to Clinic” conference, held at Trinity College, Oxford University, explores latest discoveries in immunology and molecular medicine ---- PAS002 is a proprietary DNA vaccine...
Pasithea Therapeutics Announces Results of Preclinical Study Demonstrating Tolerizing Vaccine Efficacy in Relapsing-Remitting Model of Multiple Sclerosis
August 11, 2022 08:00 ET
|
Pasithea
-- PAS002 is a proprietary DNA tolerizing vaccine construct encoding GlialCAM ---- PAS002 effectively reduces disease severity, delays onset of illness, while also reducing relapse severity ----...
Pasithea Therapeutics Urges Stockholders to Reject Activist Camac Group’s Unjustified Campaign
August 02, 2022 07:00 ET
|
Pasithea
Stockholders Should Protect Upside in Potential Groundbreaking Therapies for MS, ALS and Other Large Unmet Medical Conditions from Activist’s Apparent Cash Grab Board Unanimously Recommends...
Pasithea Therapeutics Awarded a Drug Development Research Grant
July 14, 2022 08:00 ET
|
Pasithea
-- AUD $1 million (U.S $694,000) grant transferred as part of Alpha-5 Integrin, LLC transaction ---- Provides approximately U.S. $694,000 of non-dilutive funding -- MIAMI BEACH, Fla., July 14, 2022 ...
Pasithea Therapeutics to Participate in the H.C. Wainwright 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics and Beyond
June 23, 2022 08:00 ET
|
Pasithea
MIAMI BEACH, Fla., June 23, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of...
Pasithea Therapeutics Acquires Alpha-5 Integrin, LLC
June 22, 2022 08:00 ET
|
Pasithea
- Alpha-5 is a potentially first-in-class monoclonal antibody for the treatment of amyotrophic lateral sclerosis (ALS) and other neurological diseases -- Expands pipeline across Pasithea's core...
Pasithea Therapeutics to Present at the NobleCon18 Investor Conference 2022
April 14, 2022 16:15 ET
|
Pasithea
MIAMI BEACH, Fla., April 14, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of...
Pasithea Therapeutics Announces Financial and Business Results for the Fourth Quarter and Full Year 2021 and Business Update for 2022
March 30, 2022 16:15 ET
|
Pasithea
-- Cash Balance of $52.9 million to fund operations well into 2024 ---- Initiation of a drug development program in schizophrenia ---- Initiation of a drug development program in multiple sclerosis...
Pasithea Therapeutics Announces Collaboration with The Glimpse Group
March 08, 2022 08:00 ET
|
Pasithea
- The Glimpse Group is a Virtual Reality and Augmented Reality platform company - Partnership will allow Pasithea to co-develop VR environments for patients with psychiatric disorders MIAMI...
Pasithea Therapeutics Announces Plans to Open Three New Clinics in the UK by Mid-2022
February 24, 2022 08:00 ET
|
Pasithea
-- Each clinic expected to contribute an estimated USD$5 million (£4 million) annually in revenue -- -- New London locations will provide pharmacy services, ketamine therapy, and other psychiatric...